MedTrace Logo

Intravenous Immunoglobulin After Relapse in Vasculitis

NCT00307658 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-05-22

No results posted yet for this study

Summary

The aim of this study is to study the efficacy of intravenous immunoglobulins for inducing remission in patients relapsing of systemic vasculitides.

Conditions

  • ANCA + Vasculitides Relapsing Either Under Corticosteroid
  • and Immunosuppressant Therapies or After One Year
  • Post Treatment.

Interventions

DRUG

Intravenous immunoglobulins (human immunoglobulins G)

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Loïc GUILLEVIN, MD,PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Completion
2006-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307658 on ClinicalTrials.gov